IL6 and metabolic dysfunction-associated steatohepatitis: Although several independent research groups have reported that their MSC−sEV preparations were efficacious in reducing hepatic injury and fibrosis in different mouse models of NASH [32,33,34], the potential of their MSC−sEV preparations to polarize M2 macrophages and reduce IL−6, or the effects of this potential on the development of fibrosis has not been reported.